Dr Dingle's Blog / corona virus

Is COVID -19 and pharmaceutical inflicted emergency?

Is COVID -19 and pharmaceutical inflicted emergency?

Research now presented in at least 3 top journals (Nature, Lancet, Journal of Hypertension) shows a link between blood pressure, diabetes medications and the severity of COVID-19 which explains the extremely high severity and mortality rate in people with pre-existing cardiovascular disease, hypertension and diabetes.  Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are highly recommended medications for patients with cardiovascular diseases including heart attacks, high blood pressure, diabetes and chronic kidney disease and more.

COVID-19 attaches to the cell’s surface via the ACE-2 protein – that is its sole point of entry – and what we know is that Angiotensin II Receptor Blockers (ARBs) used to lower blood pressure and diabetes increase the expression of the ACE-2 protein in the body as many as three to five times. Effectively it means the little doorway for the virus is now a huge gateway. As a result, patients on these anti-hypertensives (blood pressure) fare much worse than average.

One argument put forward by the drug companies is that there are no clinical trials. However in reality no ethics committee would ever allow a clinical trial for something potentially so deadly.

Did you know there are many studies showing natural remedies including good nutrition to manage and even reverse blood pressure and diabetes. Perhaps we need to reinvest more money and time in dealing with the problems rather than just treating the symptoms?

Examples of angiotensin II receptor blockers include:

Azilsartan (Edarbi)
Candesartan (Atacand)
Eprosartan
Irbesartan (Avapro)
Losartan (Cozaar)
Olmesartan (Benicar)
Telmisartan (Micardis)
Valsartan (Diovan)

 

Zhou, P., Yang, X., Wang, X. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020). https://doi.org/10.1038/s41586-020-2012-7

Esler, Murraya,*; Esler, Danielleb,. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? Journal of Hypertension: March 11, 2020 - Volume Publish Ahead of Print - Issue - doi: 10.1097/HJH.0000000000002450

Lei Fang, George Karakiulakis, Michael Roth Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?The Lancet. Published:March 11, 2020DOI:https://doi.org/10.1016/S2213-2600(20)30116-8

Read more →

Gut health is directly linked with respiratory infections

Gut health is directly linked with respiratory infections

There is overwhelming evidence by the way of hundreds of studies, through multiple channels to demonstrate that our gut health, probiotics and fibre are essential to our immune systems protection against many types of viruses including deadly respiratory viruses. To ignore this information in the time of Corona virus is both dangerous and irresponsible. The studies show first, that gut health is critical for both the innate (immediate) and adaptive (long term) immune system. In fact many people put the gut microbiome link as the major player in our immunity and suggest as much as 75-85% of the immune system is directly linked to the gut.

 

In addition, studies show that enhancing the gut in both human and animal studies with probiotics, prebiotics and fibre dramatically enhance the immune system and protect humans and test animals in all viruses tested against including deadly respiratory viruses. Studies have also demonstrated the enhance immune function of vaccines when prebiotics and probiotics are added, especially in the elderly where vaccines are very ineffective. All this is supported by the fact that when antibiotics are used, even from just a few days, it significantly increases the risk of viral infection, severity and mortality. The link could not be any more obvious.

 

The picture is very clear. The single best thing people can do to protect themselves and their family from respiratory infection is priming the gut and gut microbiome. No matter what state of health you are in. While the studies presented here focus on probiotics and fibre there are many actions we need to take each day to improve our gut health which I spell out in my book “Gut Secrets” with all the extra information to help build the gut as well as what causes the gut dysfunction (dysbiosis) in the first place. Ignoring this information is putting many people’s, especially the elderly and those with pre-existing health conditions at risk. To support what I am reporting here I have included more than 100 scientifically reviewed studies and there are more.

 

The gut microbiota has been shown to have influences outside the gastrointestinal tract, from the wide-ranging anti-inflammatory effects of bacterial metabolites like short-chain fatty acids to the alteration of chemical messengers like neurotransmitter production in the central nervous system. Studies also demonstrate connections between gut microbiota and organs throughout our body in regulatory functions like gut–lung, gut–brain, gut–skin, and gut–liver axes, which play an important role in many infectious and chronic diseases. As result, virtually all human diseases, including obesity, allergies, Parkinson’s disease and diabetes, have all been associated with disease-specific shifts in gut microbiome.

 

More recently, many studies emphasized the important roles of gut microbiota in shaping immunity against viral diseases in humans and numerous animal species tested and that our microbial diversity and its integrity are the key elements for deriving immunity against invading viral pathogens. Our good gut bacteria, also called commensal bacteria, provide protection against pathogens (the nasty ones) through direct competition and by the production of antibodies and activation of different chemical messengers to modulate our innate (short term) and adaptive (longer term) immune responses. As a result disruption of our gut microbial balance (dysbiosis) is associated with a variety of conditions which facilitate the establishment of acute respiratory viral infections. Our gut microbiota is therefore directly linked with regulating ourrespiratory antiviral immune response 1,2.

 

Overwhelming research now shows that probiotics are a simple and safe strategy for the prevention of viral respiratory tract infections and can modulate host immunoregulation, alleviate intestinal inflammation, normalize gut mucosal dysfunction, and downregulate hypersensitivity reactions through control of proinflammatory and anti-inflammatory chemical messengers 3-29.

Specific studies have also been done to show the benefits of probiotics in children and shown extremely positive results 31-33 and in the elderly 33-34. In a study of 196 participants were randomized to receive probiotics or a placebo daily for 6 months respiratory viral infections were 35% lower in the probiotic group compared to the placebo. 35 While, in a randomized, double-blind, placebo-controlled trial of 94 preterm infants, who are very susceptible to respiratory infections between days 3 and 60 of life, the incidence of RTIs was 76% lower in infants receiving prebiotics and probiotics 50% lower compared with those receiving the placebo. While the incidence of rhinovirus-induced episodes, which comprised 80% of all RTI episodes, was found to be 69% lower in the prebiotic and 51% lower in the probiotic groups compared with the placebo group. 30  This is supported by meta analysis and reviews which have consistently shown significant reductions in the probiotic groups and no serious adverse events related to the probiotic strain.36-38 In addition, studies have shown Lactobacillus and Bifidobacterium strains to have immunomodulatory activity and enhanced both innate and specific immune responses in adults and children  39-42

Studies on many different animal species have shown that the gut microbiome provides a low-level stimulation to the innate immune system that modulates the susceptibility of the host to viral infection and to the severity of the infection including decreased mortality 43-71 In one study after 3 days of exposure to a strain, mice were infected with the H1N1 respiratory virus showed a lower frequency of accumulated symptoms and a higher survival rates than the controls. The study also showed administration of the probiotic protects the host animal from respiratory infection by enhancing respiratory cell‐mediated immune responses following up‐regulation of lung natural killer (NK) cell activation. 54 These and many other findings demonstrate a strong induction of both innate and adaptive immunities, as well as decreased inflammation in the lung and an increase in survival rate in the mice receiving probiotics than those of the control group 55-74.

From another perspective recent randomized controlled trials indicate that even short-term antibiotic use leads to significant changes in the gut microbiota.75 While treatment with antibiotics has been shown to increase the risk of infection from multiple viruses 76 as well as, increased morbidity and mortality during influenza infection 77-81. Fortunately, experimental data on mice with no gut microbiome have demonstrated that lack of microbiome can be reversed 82.

The elderly are particularly vulnerable to seasonal influenza; indeed, approximately 90% of all influenza-related deaths occur among senior citizens. Influenza vaccines are widely used, but concerns regarding vaccine efficacy exist, especially in the elderly. Vaccination efficacy as a regular treatment however, is lower in the elderly, owing to the immunosenescence characteristic of this population 87-93. In a meta-analysis published in 2012, the evidence of vaccine protection in the elderly was lacking. 83

Low vaccine efficacy leads to inadequate protection, breakthrough infection, and influenza-related morbidity and mortality. In summary, the efficacy of the current influenza vaccine is not satisfactory. However, supplementing with probiotics and prebiotics significantly improves the effectiveness of the vaccines. In a meta analysis patients with prebiotics/ probiotics supplements were found to enhance the influenza antibody levels in all A/H1N1, A/H3N2, and B strains tested 84-85. While another meta analysis of 20 RCTs found that participants who took probiotics or prebiotics showed significant improvements after exposure to the H1N1 strain. This meta-analysis suggested that probiotics and prebiotics are effective in elevating immunogenicity by influencing rates in adults inoculated with influenza vaccines. 86 In another study of 98 nursing home residents, more than 65 years of age the administration of a single Lactobacillus strain to an elderly population increased the immune response against the influenza vaccine and decreased symptoms associated with respiratory infections.

Our respiratory microbiome is the first line of defence against viral infections and research shows a change in the gut microbiome alters the respiratory microbiome to move towards a state of dysbiosis. However, recent studies have also demonstrated that respiratory infections are associated with a change in the composition of the gut microbiota 94-100  which, as a result becomes more vulnerable to further dysbiosis and diseased states and a viscous cycle of deterioration.

Without doubt the health of our gut and lung microbiome plays a critical role in our susceptibility to respiratory infections. While physical methods to prevent the spread of corona virus are essential the next most import step is to increase the immunity in the population as a whole but more specifically those like our elderly are most susceptible. This can be achieved for as little as $1 a day and can be implemented instantly through the introduction of high quality probiotics and fibres such as Kfibre. This is a small expense when we compare it to what is happening now and the potential for pain and suffering.

To ignore this information is both irresponsible and dangerous. However, history tells us that even the best evidence will be ignored if it goes against the modern medical pharmaceutical model.

Please share with everyone you know as it might save their life.

 

References

1          Budden K.F., Gellatly S.L., Wood D.L., Cooper M.A., Morrison M., Hugenholtz P., Hansbro P.M. Emerging pathogenic links between microbiota and the gut–lung axis. Nat. Rev. Microbiol. 2017;15:55. doi: 10.1038/nrmicro.2016.142. [PubMed] [CrossRef] [Google Scholar].

2          Chen C.-J., Wu G.-H., Kuo R.-L., Shih S.-R. Role of the intestinal microbiota in the immunomodulation of influenza virus infection. Microbes Infect. 2017;19:570–579. doi: 10.1016/j.micinf.2017.09.002. [PubMed] [CrossRef] [Google Scholar].

3          Isolauri E, Sutas Y, Kankaanpaa P, Arvilommi H, Salminen S. Probiotics: effects on immunity. Am J Clin Nutr. 2001;14(Suppl 2):444S–450S. [PubMed] [Google Scholar].

4          Hatakka K, Savilahti E, Pönkä A, et al. (2001) Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. BMJ 322, 1327. [PMC free article] [PubMed] [Google Scholar]

5          Turchet P, Laurenzano M, Auboiron S, et al. (2003) Effect of fermented milk containing the probiotic Lactobacillus casei DN-114001 on winter infections in free-living elderly subjects: a randomised, controlled pilot study. J Nutr Health Aging 7, 75–77 [PubMed] [Google Scholar]

6          de Vrese M, Winkler P, Rautenberg P, et al. (2005) Effect of Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5 on common cold episodes: a double blind, randomized, controlled trial. Clin Nutr 24, 481–491 [PubMed] [Google Scholar]

7          Tubelius P, Stan V & Zachrisson A (2005) Increasing work-place healthiness with the probiotic Lactobacillus reuteri: a randomised, double-blind placebo-controlled study. Environ Health 4, 25. [PMC free article] [PubMed] [Google Scholar]

8          De Vrese M., Winkler P., Rautenberg P., Harder T., Noah C., Laue C., Ott S., Hampe J., Schreiber S., Heller K., et al. Effect of lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, b. Bifidum MF 20/5 on common cold episodes: A double blind, randomized, controlled trial. Clin. Nutr. 2005;24:481–491. doi: 10.1016/j.clnu.2005.02.006. [PubMed] [CrossRef] [Google Scholar]

9          Tiollier E, Chennaoui M, Gomez-Merino D, et al. (2007) Effect of probiotics supplementation on respiratory infections and immune and hormonal parameters during intense military training. Mil Med 9, 1006–1011 [PubMed] [Google Scholar]

10        Prodeus A, Niborski V, Kern E, et al. (2008) Effect of the Consumption of a Fermented Milk on Common Infections in Children Aged 3–6 Years, Attending Day Care Centres. Moscow: Danone Research [Google Scholar]

 

11        Kloster Smerud H, Ramstad Kleiveland C, Roll Mosland A, et al. (2008) Effect of a probiotic milk product on gastrointestinal and respiratory infections in children attending day-care. Microb Ecol Health and Dis 20, 80–85 [Google Scholar]

 

13        Niborski V, Ernouf C & Maury S (2008) Effect of the Consumption of a Fermented Milk on Common Infections in Adults Submitted to Multi-stressor Situation. Villeneuve Saint-Georges: Danone Research [Google Scholar]

 

14        Leyer GJ, Li S, Mubasher ME, et al. (2009) Probiotic effects on cold and influenza-like symptom incidence and duration in children. Pediatrics 124, E172–E179 [PubMed] [Google Scholar]

 

15        Cáceres P, Montes S, Vega N, et al. (2010) Effects of Lactobacillus rhamnosus HN001 on acute respiratory infections and intestinal secretory IgA in children. Pediatr Infect Dis J 5, 353–362 [Google Scholar]

 

16        Guillemard E, Tanguy J, Flavigny A, et al. (2010) Effects of consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 on common respiratory and gastrointestinal infections in shift workers in a randomized controlled trial. J Am Coll Nutr 29, 455–468 [PubMed] [Google Scholar]

 

17        Guillemard E, Tondu F, Lacoin F, et al. (2010) Consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial. Br J Nutr 103, 58–68 [PubMed] [Google Scholar]

 

18        Hojsak I, Abdovic S, Szajewska H, et al. (2010) Lactobacillus GG in the prevention of nosocomial gastrointestinal and respiratory tract infections. Pediatrics 125, E1171–E11E7 [PubMed] [Google Scholar]

 

19        Hojsak I, Snovak N, Abdovic S, et al. (2010) Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, double-blind, placebo-controlled trial. Clin Nutr 29, 312–316 [PubMed] [Google Scholar]

 

20        Cazzola M, Pham-Thi N, Kerihuel JC, et al. (2010) Efficacy of a synbiotic supplementation in the prevention of common winter diseases in children: a randomized, double-blind, placebo-controlled pilot study. Therapy 4, 271–278 [PubMed] [Google Scholar]

 

21        Merenstein D, Murphy M, Fokar A, et al. (2010) Use of a fermented dairy probiotic drink containing Lactobacillus casei (DN-114 001) to decrease the rate of illness in kids: the DRINK study. A patient-oriented, double-blind, cluster-randomized, placebo-controlled, clinical trial. Eur J Clin Nutr 64, 669–677 [PMC free article] [PubMed] [Google Scholar]

 

22        Berggren A, Ahren IL, Larsson N, et al. (2011) Randomised, double-blind and placebo-controlled study using new probiotic lactobacilli for strengthening the body immune defence against viral infections. Eur J Nutr 50, 203–210 [PubMed] [Google Scholar]

 

23        Kumpu M, Kekkonen RA, Kautiainen H, et al. (2012) Milk containing probiotic Lactobacillus rhamnosus GG and respiratory illness in children: a randomized, double-blind, placebo-controlled trial. Eur J Clin Nutr 66, 1020–1023 [PubMed] [Google Scholar]

 

24        Kawase M1, He F, Kubota A, Yoda K, Miyazawa K, Hiramatsu M. FEMS Immunol Med Microbiol. 2012 Mar;64(2):280-8. doi: 10.1111/j.1574. Heat-killed Lactobacillus gasseri TMC0356 protects mice against influenza virus infection by stimulating gut and respiratory immune responses

 

25        Smith TJ, Rigassio-Radler D, Denmark R, et al. (2012) Effect of Lactobacillus rhamnosus LGG® and Bifidobacterium animalis ssp. lactis BB-12® on health-related quality of life in college students affected by upper respiratory infections. Br J Nutr 109, 1999–2007 [PubMed] [Google Scholar]

 

26        Yosuke Kikuchi, 1 Ayami Kunitoh-Asari, Katsuyuki Hayakawa, 1 Shinjiro Imai, 1 , 2 Kenji Kasuya, 3 Kimio Abe, 4 Yu Adachi, 5 Shin-ichi Fukudome, 1 Yoshimasa Takahashi, 5 and Satoshi Hachimura 6 , *  PLoS One. 2014; 9(1): e86416. doi: 10.1371/journal.pone.0086416. Oral Administration of Lactobacillus plantarum Strain AYA Enhances IgA Secretion and Provides Survival Protection against Influenza Virus Infection in Mice

 

27        Lehtoranta L1, Pitkäranta A, Korpela R. Eur J Clin Microbiol Infect Dis. 2014 Aug;33(8):1289-302. doi: 10.1007/s10096-014-2086-y. Epub 2014 Mar 18.Probiotics in respiratory virus infections.

 

28        West NP, Horn PL, Pyne DB, Gebski VJ, Lahtinen SJ, Fricker PA, Cripps AW. Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy physically active individuals. Clinical Nutrition. 2014;33:581–587. [PubMed] [Google Scholar]

 

29        Bae JY1, Kim JI1, Park S1, Yoo K1, Kim IH2, Joo W3, Ryu BH3, Park MS1, Lee I1, Park MS1.J Microbiol Biotechnol. 2018 Jun 28;28(6):893-901. doi: 10.4014/jmb.1804.04001. Effects of Lactobacillus plantarum and Leuconostoc mesenteroides Probiotics on Human Seasonal and Avian Influenza Viruses.

30        J Allergy Clin Immunol. 2014 Feb;133(2):405-13. doi: 10.1016/j.jaci.2013.08.020. Epub 2013 Oct 13. Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: a randomized, placebo-controlled trial. Luoto R1, Ruuskanen O2, Waris M3, Kalliomäki M2, Salminen S4, Isolauri E2.

31        Leyer G.J., Li S., Mubasher M.E., Reifer C., Ouwehand A.C. Probiotic effects on cold and influenza-like symptom incidence and duration in children. Pediatrics. 2009;124:e172–e179. doi: 10.1542/peds.2008-2666. [PubMed] [CrossRef] [Google Scholar]

 

32        Waki N, Matsumoto M, Fukui Y, Suganuma H. Effects of probiotic Lactobacillus brevis KB290 on incidence of influenza infection among schoolchildren: an open-label pilot study. Lett Appl Microbiol. 2014;59:565–571. [PMC free article] [PubMed] [Google Scholar]

 

33        Leyer GJ, Li S, Mubasher ME, Reifer C, Ouwehand AC. Probiotic effects on cold and influenza-like symptom incidence and duration in children. Pediatrics. 2009;124:e172–e179. [PubMed] [Google Scholar]

 

34        Yaqoob P. Ageing, immunity and influenza: A role for probiotics? Proc. Nutr. Soc. 2014;73:309–317. doi: 10.1017/S0029665113003777. [PubMed] [CrossRef] [Google Scholar]

 

35        J Am Geriatr Soc. 2018 Jul;66(7):1346-1352. doi: 10.1111/jgs.15396. Epub 2018 May 9. Probiotics to Prevent Respiratory Infections in Nursing Homes: A Pilot Randomized Controlled Trial. Wang B1, Hylwka T1, Smieja M1, Surrette M2, Bowdish DME1, Loeb M1.

 

36        Vouloumanou EK1, Makris GC, Karageorgopoulos DE, Falagas ME. Int J Antimicrob Agents. 2009 Sep;34(3):197.e1-10. doi: 10.1016/j.ijantimicag.2008.11.005. Epub 2009 Jan 28. Probiotics for the prevention of respiratory tract infections: a systematic review.

 

37        Sarah King, 1 Julie Glanville,1,* Mary Ellen Sanders, 2 Anita Fitzgerald, 1 and Danielle Varley 1 . Br J Nutr. 2014 Jul 14; 112(1): 41–54.. doi: 10.1017/S0007114514000075. Effectiveness of probiotics on the duration of illness in healthy children and adults who develop common acute respiratory infectious conditions: a systematic review and meta-analysis

38        Ozen M1, Kocabas Sandal G, Dinleyici EC. Expert Opin Biol Ther. 2015 Jan;15(1):9-20. doi: 10.1517/14712598.2015.980233. Epub 2014 Nov 28.Probiotics for the prevention of pediatric upper respiratory tract infections: a systematic review.

39        Olivares M, Díaz-Ropero MP, Gómez N, Sierra S, Lara-Villoslada F, Maldonado JA, Martín R, Rodríguez JM, Xaus J. The consumption of two probiotic strains, Lactobacillus gasseri CECT5714 and Lactobacillus coryniformis CECT5711, boost the immune system of healthy adults. Int Microbiol. 2006;9:47–52. [PubMed] [Google Scholar]

 

40        Lara-Villoslada F, Sierra S, Boza J, Xaus J, Olivares M. Beneficial effects of consumption of a dairy product containing two probiotic strains, Lactobacillus coryniformis CECT5711 and Lactobacillus gasseri CECT5714 in healthy children. Nutr Hosp. 2007;22(4):496–502. [PubMed] [Google Scholar]

 

41        Lehtoranta L1, Pitkäranta A, Korpela R.  Eur J Clin Microbiol Infect Dis. 2014 Aug;33(8):1289-302. doi: 10.1007/s10096-014-2086-y. Epub 2014 Mar 18.Probiotics in respiratory virus infections.

 

42        R.B. Turner,1 J.A. Woodfolk,2 L. Borish,2,3 J.W. Steinke,2 J.T. Patrie,4 L.M. Muehling,2 S. Lahtinen,5 and M.J. Lehtinen Benef Microbes. 2017 Apr 26; 8(2): 207–215. doi: 10.3920/BM2016.0160 Effect of probiotic on innate inflammatory response and viral shedding in experimental rhinovirus infection – a randomised controlled trial

 

43        Hori T, Kiyoshima J, Shida K, Yasui H. Effect of intranasal administration of Lactobacillus casei Shirota on influenza virus infection of upper respiratory tract in mice. Clin Diagn Lab Immunol. 2001 May;8(3):593-7.

 

44        Tetsuji Hori,* Junko Kiyoshima, Kan Shida, and Hisako Yasui. Effect of Intranasal Administration of Lactobacillus casei Shirota on Influenza Virus Infection of Upper Respiratory Tract in Mice. Clin Diagn Lab Immunol. 2001 May; 8(3): 593–597.  [PMC free article] [PubMed] [CrossRef] [Google Scholar]

 

45        Blum S, Haller D, Pfeifer A, Schiffrin EJ (2002) Probiotics and immune response. Clin Rev Allergy Immunol 22(3): 287–309. [PubMed] [Google Scholar]

Perdigon G, Fuller R, Raya R (2001) Lactic acid bacteria and their effect on the immune system. Curr Issues Intest Microbiol 2(1): 27–42. [PubMed] [Google Scholar]

 

46        Heczko PB, Strus M, Kochan P (2006) Critical evaluation of probiotic activity of lactic acid bacteria and their effects. J Physiol Pharmacol 57 Suppl 95–12. [PubMed] [Google Scholar]

 

47        de Vrese M, Winkler P, Rautenberg P, Harder T, Noah C, Laue C, et al. Probiotic bacteria reduced duration and severity but not the incidence of common cold episodes in a double blind, randomized, controlled trial. Vaccine (2006) 24:6670–4. 10.1016/j.vaccine.2006.05.048 [PubMed] [CrossRef] [Google Scholar]

 

48        Olivares M, az-Ropero MP, Sierra S, Lara-Villoslada F, Fonolla J, Navas M, et al. Oral intake of Lactobacillus fermentum CECT5716 enhances the effects of influenza vaccination. Nutrition. 2007;23:254–260. [PubMed] [Google Scholar]

 

49        Vouloumanou EK, Makris GC, Karageorgopoulos DE, Falagas ME. Probiotics for the prevention of respiratory tract infections: a systematic review. Int J Antimicrob Agents (2009) 34:197.e1–10. 10.1016/j.ijantimicag.2008.11.005 [PubMed] [CrossRef] [Google Scholar]

50        Makino S, Ikegami S, Kume A, Horiuchi H, Sasaki H, Orii N. Br J Nutr. 2010 Reducing the risk of infection in the elderly by dietary intake of yoghurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1. Oct;104(7):998-1006. doi: 10.1017/S000711451000173X. Epub 2010 May 21.

51        Nagai T1, Makino S, Ikegami S, Itoh H, Yamada H Int Immunopharmacol. 2011 Dec;11(12):2246-50. doi: 10.1016/j.intimp.2011.09.012. Epub 2011 Oct 8. Effects of oral administration of yogurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 and its exopolysaccharides against influenza virus infection in mice.

 

52        Ichinohe T., Pang I.K., Kumamoto Y., Peaper D.R., Ho J.H., Murray T.S., Iwasaki A. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc. Natl. Acad. Sci. USA. 2011;108:5354–5359. doi: 10.1073/pnas.1019378108

 

53        Kawase M, He F, Kubota A, Harata G, Hiramatsu M. Oral administration of lactobacilli from human intestinal tract protects mice against influenza virus infection. Lett. Appl. Microbiol. 2010;51:6–10. doi: 10.1111/j.1472-765X.2010.02849.x. [PubMed] [CrossRef] [Google Scholar]

 

54        Harata G, He F, Hiruta N, Kawase M, Kubota A, Hiramatsu M, et al. Intranasal administration of Lactobacillus rhamnosus GG protects mice from H1N1 influenza virus infection by regulating respiratory immune responses 2. Lett Appl Microbiol. 2010;50:597–602. [PubMed] [Google Scholar]

 

55        Takeda S1, Takeshita M, Kikuchi Y, Dashnyam B, Kawahara S, Yoshida H, Watanabe W, Muguruma M, Kurokawa M. Int Immunopharmacol. Efficacy of oral administration of heat-killed probiotics from Mongolian dairy products against influenza infection in mice: alleviation of influenza infection by its immunomodulatory activity through intestinal immunity.  2011 Dec;11(12):1976-83. doi: 10.1016/j.intimp.2011.08.007. Epub 2011 Aug 24.

 

56        Youn HN, et al. Intranasal administration of live Lactobacillus species facilitates protection against influenza virus infection in mice. Antiviral Res. 2012;93:138–143. doi: 10.1016/j.antiviral.2011.11.004. [PubMed] [CrossRef] [Google Scholar]

 

57        Pang IK, Iwasaki A. Control of antiviral immunity by pattern recognition and the microbiome. Immunological Reviews. 2012;245:209–226. [PMC free article] [PubMed] [Google Scholar]

 

58        Goto H, Sagitani A, Ashida N, et al. Anti-influenza virus effects of both live and non-live Lactobacillus acidophilus L-92 accompanied by the activation of innate immunity. Br J Nutr. 2013;110:1810–1818. [PubMed] [Google Scholar]

 

59        Nakayama Y, et al. Oral administration of Lactobacillus gasseri SBT2055 is effective for preventing influenza in mice. Sci. Rep. 2014;4:4638. doi: 10.1038/srep04638. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

60        Yosuke Nakayama,1,3 Tomohiro Moriya,2,3 Fumihiko Sakai,2 Noriko Ikeda,1 Takuya Shiozaki,1 Tomohiro Hosoya,2 Hisako Nakagawa,1 and Tadaaki Miyazakia,1 Sci Rep. 2014; 4: 4638. doi: 10.1038/srep04638 Oral administration of Lactobacillus gasseri SBT2055 is effective for preventing influenza in mice

61        Kawahara T1, Takahashi T, Oishi K, Tanaka H, Masuda M, Takahashi S, Takano M, Kawakami T, Fukushima K, Kanazawa H, Suzuki T. Microbiol Immunol. 2015 Jan;59(1):1-12. doi: 10.1111/1348-0421.12210. Consecutive oral administration of Bifidobacterium longum MM-2 improves the defense system against influenza virus infection by enhancing natural killer cell activity in a murine model.

 

62        Zelaya H1, Tada A, Vizoso-Pinto MG, Salva S, Kanmani P, Agüero G, Alvarez S, Kitazawa H, Villena J. Inflamm Res. 2015 Aug;64(8):589-602. doi: 10.1007/s00011-015-0837-6. Epub 2015 Jun 14. Nasal priming with immunobiotic Lactobacillus rhamnosus modulates inflammation-coagulation interactions and reduces influenza virus-associated pulmonary damage.

 

63        Caroline M. Percopo,a Tyler A. Rice,a Todd A. Brenner,a Kimberly D. Dyer,a Janice L. Luo,a Kishore Kanakabandi,b Daniel E. Sturdevant,b Stephen F. Porcella,b Joseph B. Domachowske,c Jesse D. Keicher,d,1 and Helene F. Rosenberga,* Antiviral Res. 2015 Sep; 121: 109–119. doi: 10.1016/j.antiviral.2015.07.001. Lactobacillus administered post-exposure averts the lethal sequelae of respiratory virus infection. Immunobiotic

64        Kimberly D. Dyer,a Rebecca A. Drummond,b Tyler A. Rice,a,* Caroline M. Percopo,a Todd A. Brenner,a Derek A. G. Barisas,a,* Kendal A. Karpe,a,* Martin L. Moore,c and Helene F. RosenbergJ Virol. 2016 Jan 15; 90(2): 979–991.. doi: 10.1128/JVI.02279-15 Priming of the Respiratory Tract with Immunobiotic Lactobacillus plantarum Limits Infection of Alveolar Macrophages with Recombinant Pneumonia Virus of Mice (rK2-PVM)

65        Jeong AhSongacHee JooKimaSeong KeunHongaDong HoonLeeaSang WonLeeaChang SeonSongaKi TaekKimbIn SooChoiaJoong BokLeeaSeung YongParka. Oral intake of Lactobacillus rhamnosus M21 enhances the survival rate of mice lethally infected with influenza virus. Journal of Microbiology, Immunology and Infection Volume 49, Issue 1, February 2016, Pages 16-23

66        Yitbarek A., Taha-Abdelaziz K., Hodgins D.C., Read L., Nagy É., Weese J.S., Caswell J.L., Parkinson J., Sharif S. Gut microbiota-mediated protection against influenza virus subtype H9N2 in chickens is associated with modulation of the innate responses. Sci. Rep. 2018;8:13189. doi: 10.1038/s41598-018-31613-0. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

 

67        Mahooti M1,2, Abdolalipour E1,2, Salehzadeh A2, Mohebbi SR3, Gorji A4,5, Ghaemi A6,7.

 World J Microbiol Biotechnol. 2019 Jun 3;35(6):91. doi: 10.1007/s11274-019-2667-0. Immunomodulatory and prophylactic effects of Bifidobacterium bifidum probiotic strain on influenza infection in mice.

 

68        Liu YS1, Liu Q1, Jiang YL1, Yang WT1, Huang HB1, Shi CW1, Yang GL1, Wang CF1. J Microbiol Biotechnol. 2019 Dec 15. doi: 10.4014/jmb.1909.09041. Surface-displayed porcine IFN-λ3 in Lactobacillus plantarum inhibits porcine enteric coronavirus infection of porcine intestinal epithelial cells.

69        Choi H, Lee SI, Sureshkumar S, Jeon MH, Kim JS, Park MR, Kim KW, Jeon IS, Lee S, Byun SJ. Acta Vet Hung. 2019 Dec;67(4):610-618. doi: 10.1556/004.2019.060. Avian influenza virus transmission is suppressed in chickens fed Lactobacillus paracasei expressing the 3D8 single-chain variable fragment protein.

70        Kei Eguchi,#1 Naoki Fujitani,#2 Hisako Nakagawa,2 and Tadaaki Miyazaki2 Sci Rep. 2019; 9: 4812. doi: 10.1038/s41598-019-39602-7. Prevention of respiratory syncytial virus infection with probiotic lactic acid bacterium Lactobacillus gasseri SBT2055

 

71        Figueroa T1, Bessière P1, Coggon A1, Bouwman KM2,3, van der Woude R2, Delverdier M1, Verheije MH3, de Vries RP2, Volmer R4. J Virol. 2020 Feb 26. pii: JVI.00289-20. doi: 10.1128/JVI.00289-20. THE MICROBIOTA CONTRIBUTES TO THE CONTROL OF HIGHLY PATHOGENIC H5N9 INFLUENZA VIRUS REPLICATION IN DUCKS.

 

72        Yasui H, Kiyoshima J, Hori T (2004) Reduction of influenza virus titer and protection against influenza virus infection in infant mice fed Lactobacillus casei Shirota. Clin Diagn Lab Immunol 11(4): 675–679. [PMC free article] [PubMed] [Google Scholar]

 

73        Izumo T, Maekawa T, Ida M, Noguchi A, Kitagawa Y, et al. (2010) Effect of intranasal administration of Lactobacillus pentosus S-PT84 on influenza virus infection in mice. Int Immunopharmacol 10(9): 1101–1106.

 

74        . Lee YN1, Youn HN, Kwon JH, Lee DH, Park JK, Yuk SS, Erdene-Ochir TO, Kim KT, Lee JB, Park SY, Choi IS, Song CS. Antiviral Res. 2013 May;98(2):284-90. doi: 10.1016/j.antiviral.2013.03.013. Epub 2013 Mar 21. Sublingual administration of Lactobacillus rhamnosus affects respiratory immune responses and facilitates protection against influenza virus infection in mice

 

75        Doan T, Arzika AM, Ray KJ, et al. Gut Microbial Diversity in Antibiotic-Naive Children After Systemic Antibiotic Exposure: A Randomized Controlled Trial. Clin. Infect. Dis 2017;64:1147–1153. [PMC free article] [PubMed] [Google Scholar]

 

76        Larissa B. Thackray,1 Scott A. Handley,2 Matthew J. Gorman,1 Subhajit Poddar,1 Prachi Bagadia,2 Carlos G. Briseño,2 Derek J. Theisen,2 Qing Tan,1 Barry L. Hykes, Jr.,2 Hueylie Lin,1 Tiffany M. Lucas,1 Chandni Desai,2 Jeffrey I. Gordon,3,4 Kenneth M. Murphy,2,5 Herbert W. Virgin,2,6 and Michael S. Diamond1,2,6,7,8,*Oral Antibiotic Treatment of Mice Exacerbates the Disease Severity of Multiple Flavivirus Infections. Cell Rep. 2018 Mar 27; 22(13): 3440–3453.e6.  doi: 10.1016/j.celrep.2018.03.001

 

77        Ichinohe T, Pang IK, Kumamoto Y, Peaper DR, Ho JH, Murray TS, et al. . Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc Natl Acad Sci USA. (2011) 108:5354–9. 10.1073/pnas.1019378108 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

 

78        Abt M.C., Osborne L.C., Monticelli L.A., Doering T.A., Alenghat T., Sonnenberg G.F., Paley M.A., Antenus M., Williams K.L., Erikson J., et al. Commensal Bacteria Calibrate the Activation Threshold of Innate Antiviral Immunity. Immunity. 2012;37:158–170. doi: 10.1016/j.immuni.2012.04.011. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

 

79        Doan T, Arzika AM, Ray KJ, et al. Gut Microbial Diversity in Antibiotic-Naive Children After Systemic Antibiotic Exposure: A Randomized Controlled Trial. Clin. Infect. Dis 2017;64:1147–1153. [PMC free article] [PubMed] [Google Scholar]

 

80        Parker EPK, Praharaj I, John J, et al. Changes in the intestinal microbiota following the administration of azithromycin in a randomised placebo-controlled trial among infants in south India. Sci Rep 2017;7:9168. [PMC free article] [PubMed] [Google Scholar]

 

81        Chikara Ogimi, MD,1,2,3 Elizabeth M. Krantz, MS,1 Jonathan L. Golob, MD, PhD,1,4,5 Alpana Waghmare, MD,1,2,3 Catherine Liu, MD,1,4,5 Wendy M. Leisenring, ScD,5,6 Christopher R. Woodard, BS,1 Sara Marquis, MPH,1 Jane M. Kuypers, PhD,1,7 Keith R. Jerome, MD, PhD,1,7 Steven A. Pergam, MD, MPH,1,4,5 David N. Fredricks, MD,1,4,5 Mohamed L. Sorror, MD, MSc,4,5 Janet A. Englund, MD,2,3 and Michael Boeckh, MD, PhD1,4,  Biol Blood Marrow Transplant. 2018 Nov; 24(11): 2293–2301.  Published online 2018 May 16. doi: 10.1016/j.bbmt.2018.05.016. Antibiotic exposure prior to respiratory viral infection is associated with progression to lower respiratory tract disease in allogeneic hematopoietic cell transplant recipients

 

82        Herbst T, Sichelstiel A, Schar C, Yadava K, Burki K, Cahenzli J, et al. . Dysregulation of allergic airway inflammation in the absence of microbial colonization. Am J Respir Crit Care Med. (2011) 184:198–205. 10.1164/rccm.201010-1574OC [PubMed] [CrossRef] [Google Scholar]

83        French PW, Penny R. Use of probiotic bacteria as an adjuvant for an influenza vaccine. Int J Probiotics Prebiotics. 2009;4(3):175–182. [Google Scholar]

 

84        Tzu-Lin Yeh,1 Pei-Ching Shih,1 Shu-Jung Liu,2 Chao-Hsu Lin,3 Jui-Ming Liu,4,5 Wei-Te Lei,#3,* and Chien-Yu Lin#3,Drug Des Devel Ther. 2018; 12: 217–230. doi: 10.2147/DDDT.S155110. The influence of prebiotic or probiotic supplementation on antibody titers after influenza vaccination: a systematic review and meta-analysis of randomized controlled trials *

 

85        Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis. 2007;7:658–666. doi: 10.1016/S1473-3099(07)70236-0. [PubMed] [CrossRef] [Google Scholar]

 

86        Nutrients. 2017 Nov; 9(11): 1175.. doi: 10.3390/nu9111175. Effect of Probiotics and Prebiotics on Immune Response to Influenza Vaccination in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Wei-Te Lei,1 Pei-Ching Shih,2 Shu-Jung Liu,3 Chien-Yu Lin,1 and Tzu-Lin Yeh2,*

 

87        Hernandez-Vargas EA, Wilk E, Canini L, Toapanta FR, Binder SC, Uvarovskii A, Ross TM, Guzmán CA, Perelson AS, Meyer-Hermann M. Effects of aging on influenza virus infection dynamics. J Virol. 2014;88(8):4123–4131. doi: 10.1128/JVI.03644-13. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

 

88        Bernstein E, Kaye D, Abrutyn E, Gross P, Dorfman M, Murasko DM. Immune response to influenza vaccination in a large healthy elderly population. Vaccine. 1999;17(1):82–94. doi: 10.1016/S0264-410X(98)00117-0. [PubMed] [CrossRef] [Google Scholar]

 

89        Olivares M, Díaz-Ropero MP, Sierra S, Lara-Villoslada F, Fonollá J, Navas M, Rodríguez JM, Xaus J. Oral intake of Lactobacillus fermentum CECT5716 enhances the effects of influenza vaccination. Nutrition. 2007;23(3):254–260. doi: 10.1016/j.nut.2007.01.004. [PubMed] [CrossRef] [Google Scholar]

 

90        Boge T, Rémigy M, Vaudaine S, Tanguy J, Bourdet-Sicard R, van der Werf S. A probiotic fermented dairy drink improves antibody response to influenza vaccination in the elderly in two randomised controlled trials. Vaccine. 2009;27(41):5677–5684. doi: 10.1016/j.vaccine.2009.06.094. [PubMed] [CrossRef] [Google Scholar]

91        Lisa E Davidson,1 Anne-Maria Fiorino,2 David R Snydman,1 and Patricia L Hibberd1,2 Eur J Clin Nutr. 2011 Apr; 65(4): 501–507. doi: 10.1038/ejcn.2010.289. Lactobacillus GG as an Immune Adjuvant for Live Attenuated Influenza Vaccine in Healthy Adults: A Randomized Double Blind Placebo Controlled Trial

92        Fang H, Elina T, Heikki A, Seppo S. Modulation of humoral immune response through probiotic intake. FEMS Immunol Med Microbiol. 2000;29:47–52. [PubMed] [Google Scholar]

 

93        Juristo Fonollá,1 Carlos Gracián,2,3,4 Jose A. Maldonado-Lobón,1 Carlos Romero,5 Alicia Bédmar,6 Juan C. Carrillo,3 Carmen Martín-Castro,3 Antonio L. Cabrera,3 Jose M. García-Curiel,4 Carlos Rodríguez,1 Sara Sanbonmatsu,7 Mercedes Pérez-Ruiz,7 Jose M. Navarro,7 and Mónica Olivares1 Eur J Nutr. 2019; 58(1): 83–90. doi: 10.1007/s00394-017-1573-1. Effects of Lactobacillus coryniformis K8 CECT5711 on the immune response to influenza vaccination and the assessment of common respiratory symptoms in elderly subjects: a randomized controlled trial

 

94        Wang J, Li F, Wei H, Lian Z-X, Sun R, Tian Z. 2014. Respiratory influenza virus infection induces intestinal immune injury via microbiota-mediated Th17 cell-dependent inflammation. J Exp Med 211:2397–2410. doi:10.1084/jem.20140625. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

 

95        Deriu E, Boxx GM, He X, Pan C, Benavidez SD, Cen L, Rozengurt N, Shi W, Cheng G. 2016. Influenza virus affects intestinal microbiota and secondary Salmonella Infection in the gut through type I interferons. PLoS Pathog 12:e1005572. doi:10.1371/journal.ppat.1005572. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

 

96        Bartley JM, Zhou X, Kuchel GA, Weinstock GM, Haynes L. 2017. Impact of age, caloric restriction, and influenza infection on mouse gut microbiome: an exploratory study of the role of age-related microbiome changes on influenza responses. Front Immunol 8:1164. doi:10.3389/fimmu.2017.01164. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

 

97        Groves HT, Cuthbertson L, James P, Moffatt MF, Cox MJ, Tregoning JS. 2018. Respiratory disease following viral lung infection alters the murine gut microbiota. Front Immunol 9:182. doi:10.3389/fimmu.2018.00182. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

 

98        Yildiz S, Mazel-Sanchez B, Kandasamy M, Manicassamy B, Schmolke M. 2018. Influenza A virus infection impacts systemic microbiota dynamics and causes quantitative enteric dysbiosis. Microbiome 6:9. doi:10.1186/s40168-017-0386-z. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

 

99        Hanada S, Pirzadeh M, Carver KY, Deng JC. 2018. Respiratory viral infection-induced microbiome alterations and secondary bacterial pneumonia. Front Immunol 9:2640. doi:10.3389/fimmu.2018.02640. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

 

100      Muhammad Abaidullah,1,† Shuwei Peng,1,† Muhammad Kamran,2 Xu Song,1 and Zhongqiong Yin1, Viruses. 2019 Aug; 11(8): 681. doi: 10.3390/v11080681 Current Findings on Gut Microbiota Mediated Immune Modulation against Viral Diseases in Chicken.

 

 

 

Read more →

Corona virus action plan. Putting it in perspective

Corona virus action plan. Putting it in perspective

There are many strategies to help build your immune system and protect you from the corona virus

 

Read more →